{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:45:55Z","timestamp":1777949155963,"version":"3.51.4"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"DOI":"10.1093\/oncolo\/oyag101","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:44:07Z","timestamp":1775648647000},"source":"Crossref","is-referenced-by-count":0,"title":["EMBARK in biochemically recurrent prostate cancer: a journey for some but not most"],"prefix":"10.1093","volume":"31","author":[{"given":"Melissa L","family":"Abel","sequence":"first","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-1332","authenticated-orcid":false,"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-8636","authenticated-orcid":false,"given":"Ravi A","family":"Madan","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2026050311213623000_oyag101-B1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa2510310","article-title":"Improved survival with enzalutamide in biochemically recurrent prostate cancer","volume":"394","author":"Shore","year":"2026","journal-title":"N Engl J Med"},{"key":"2026050311213623000_oyag101-B2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050311213623000_oyag101-B3","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1200\/JCO.2018.36.15_suppl.5018","article-title":"Timing of androgen deprivation therapy for prostate cancer patients after radiation: planned combined analysis of two randomized phase 3 trials","volume":"36","author":"Loblaw","year":"2018","journal-title":"JCO"},{"key":"2026050311213623000_oyag101-B4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.euo.2021.04.008","article-title":"Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (tax3503)","volume":"4","author":"Morris","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2026050311213623000_oyag101-B5","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"key":"2026050311213623000_oyag101-B6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/CCO.0000000000001030","article-title":"Biochemically recurrent prostate cancer in the era of embark and PSMA pet imaging: everything has changed, except the patients","volume":"36","author":"Einstein","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"2026050311213623000_oyag101-B7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.urology.2023.10.018","article-title":"National long-term survival estimates after radical prostatectomy for prostate cancer","volume":"184","author":"Stensland","year":"2024","journal-title":"Urology"},{"key":"2026050311213623000_oyag101-B8","article-title":"PSA doubling time (PSADT) \u22646 months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (DMET)","volume":"34","author":"Suzman","journal-title":"J Clin Oncol"},{"key":"2026050311213623000_oyag101-B9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"2026050311213623000_oyag101-B10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer","volume":"9","author":"Madan","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026050311213623000_oyag101-B11","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1200\/JCO.24.01134","article-title":"Systemic treatment for biochemical recurrence of localized prostate cancer: do not embark on when, if the answer is how","volume":"42","author":"Tombal","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026050311213623000_oyag101-B12","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1200\/JCO.2025.43.16_suppl.5098","article-title":"Prospective monitoring of prostate specific membrane antigen\u2013positive biochemically recurrent prostate cancer (psma+ bcr): preliminary data from 6-month PSMA follow-up","volume":"43","author":"Madan","year":"2025","journal-title":"JCO"},{"key":"2026050311213623000_oyag101-B13","first-page":"JCO2501693","article-title":"National cancer institute\u2019s working group on biochemically recurrent prostate cancer: clinical trial design considerations","author":"Einstein","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag101\/68017724\/oyag101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag101\/68017724\/oyag101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag101\/68017724\/oyag101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:09:00Z","timestamp":1777842540000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag101\/8650355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag101","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,8]]},"article-number":"oyag101"}}